Bioresorbable Electronic Stent Could Provide Feedback, Therapy

Every year, an estimated half-million Americans undergo surgery to have a stent prop open a coronary artery narrowed by plaque. But sometimes the mesh tubes get clogged. Scientists report a new kind of multi-tasking stent that could minimize the risks associated with the procedure. It can sense blood flow and temperature, store and transmit the information for analysis and can be absorbed by the body after it finishes its job.

Doctors have been implanting stents to unblock coronary arteries for 30 years. During that time, the devices have evolved from bare metal, mesh tubes to coated stents that can release drugs to prevent reclogging. But even these are associated with health risks. So researchers have been working on versions that the body can absorb to minimize the risk that a blood clot will form. And now Dae-Hyeong Kim, Seung Hong Choi, Taeghwan Hyeon and colleagues are taking that idea a step further.

The researchers developed and tested in animals a drug-releasing electronic stent that can provide diagnostic feedback by measuring blood flow, which slows when an artery starts narrowing. The device can also heat up on command to speed up drug delivery, and it can dissolve once it’s no longer needed.

RELATED ARTICLES

A new study lends further evidence to a suspected link between abnormal breast growth in young boys--called prepubertal gynecomastia--and regular exposure to lavender or tea tree oil, by finding that key chemicals in these common plant-derived oils act as endocrine-disrupting chemicals.

Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.